open access

Vol 29, No 5 (2022)
Experts' Viewpoint
Submitted: 2022-07-02
Accepted: 2022-08-26
Published online: 2022-09-16
Get Citation

TIMES TO ACT. Italian-Spanish-Polish-Uzbek Expert Forum Position Paper 2022. Dyslipidemia and arterial hypertension: The two most important and modifiable risk factors in clinical practice

Krzysztof J. Filipiak1, Miguel Camafort Babkowski2, Matteo Cameli3, Stefano Carugo4, Claudio Ferri5, Djamshid B. Irisov6, Krzysztof Narkiewicz7, Ulugbek Nizamov8, Leopoldo Pérez de Isla9, Anna Tomaszuk-Kazberuk10, Andrea Ungar11, Aleksandra Gąsecka12
·
Pubmed: 36117294
·
Cardiol J 2022;29(5):730-738.
Affiliations
  1. Institute of Clinical Sciences, Maria Sklodowska-Curie Medical Academy, Warsaw, Poland
  2. Hypertension Unit, Hospital Clínic, University of Barcelona, Barcelona, Spain
  3. Department of Medical Biotechnologies, Division of Cardiology, University of Siena, Siena, Italy
  4. Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy; Cardiology Unit, Department of Internal Medicine, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico of Milan, Milan, Italy
  5. University of L’Aquila, MeSVA Department and San Salvatore Hospital, UOC Internal Medicine & Neohrology, Hypertension and Cardiovascular Prevention Unit, L’Aquila, Italy
  6. Cardiac Arrhythmias Department, Republican Specialised Center of Cardiology, Tashkent, Uzbekistan
  7. Chair and Department of Hypertension and Diabetology, Medical University of Gdansk, Gdansk, Poland
  8. Department of Ischemic Heart Disease and Atherosclerosis, Republican Specialised Center of Cardiology, Tashkent, Uzbekistan
  9. Department of Cardiology, Hospital Clínico San Carlos, Madrid, Spain
  10. Department of Cardiology, Medical University of Bialystok, Bialystok, Poland
  11. Geriatric and Intensive Care Medicine, Hypertension Centre, University of Florence and Careggi Hospital, Florence, Italy
  12. 1st Chair and Department of Cardiology, Medical University of Warsaw, Poland

open access

Vol 29, No 5 (2022)
POSITION PAPER
Submitted: 2022-07-02
Accepted: 2022-08-26
Published online: 2022-09-16

Abstract

Hypertension and lipid disorders are two of the main cardiovascular risk factors. Both risk factors — if detected early enough — can be controlled and treated with modern, effective drugs, devoid of significant side effects, available in four countries as different as Italy, Spain, Poland, and Uzbekistan. The aim herein, was to develop this TIMES TO ACT consensus to raise the awareness of the available options of the modern and intensified dyslipidemia and arterial hypertension treatments. The subsequent paragraphs involves consensus and discussion of the deleterious effects of COVID-19 in the cardiovascular field, the high prevalence of hypertension and lipid disorders in our countries and the most important reasons for poor control of these two factors. Subsequently proposed, are currently the most efficient and safe therapeutic options in treating dyslipidemia and arterial hypertension, focusing on the benefits of single-pill combination (SPCs) in both conditions. An accelerated algorithm is proposed to start the treatment with a PCSK9 inhibitor, if the target low-density-lipoprotein values have not been reached. As most patients with hypertension and lipid disorders present with multiple comorbidities, discussed are the possibilities of using new SPCs, combining modern drugs from different therapeutic groups, which mode of action does not confirm the “class effect”. We believe our consensus strongly advocates the need to search for patients with cardiovascular risk factors and intensify their lipid-lowering and antihypertensive treatment based on SPCs will improve the control of these two basic cardiovascular risk factors in Italy, Spain, Poland and Uzbekistan.

Abstract

Hypertension and lipid disorders are two of the main cardiovascular risk factors. Both risk factors — if detected early enough — can be controlled and treated with modern, effective drugs, devoid of significant side effects, available in four countries as different as Italy, Spain, Poland, and Uzbekistan. The aim herein, was to develop this TIMES TO ACT consensus to raise the awareness of the available options of the modern and intensified dyslipidemia and arterial hypertension treatments. The subsequent paragraphs involves consensus and discussion of the deleterious effects of COVID-19 in the cardiovascular field, the high prevalence of hypertension and lipid disorders in our countries and the most important reasons for poor control of these two factors. Subsequently proposed, are currently the most efficient and safe therapeutic options in treating dyslipidemia and arterial hypertension, focusing on the benefits of single-pill combination (SPCs) in both conditions. An accelerated algorithm is proposed to start the treatment with a PCSK9 inhibitor, if the target low-density-lipoprotein values have not been reached. As most patients with hypertension and lipid disorders present with multiple comorbidities, discussed are the possibilities of using new SPCs, combining modern drugs from different therapeutic groups, which mode of action does not confirm the “class effect”. We believe our consensus strongly advocates the need to search for patients with cardiovascular risk factors and intensify their lipid-lowering and antihypertensive treatment based on SPCs will improve the control of these two basic cardiovascular risk factors in Italy, Spain, Poland and Uzbekistan.

Get Citation

Keywords

cardiovascular prevention, hypertension, hypercholesterolemia, single-pill combination (SPC)

About this article
Title

TIMES TO ACT. Italian-Spanish-Polish-Uzbek Expert Forum Position Paper 2022. Dyslipidemia and arterial hypertension: The two most important and modifiable risk factors in clinical practice

Journal

Cardiology Journal

Issue

Vol 29, No 5 (2022)

Article type

Experts' Viewpoint

Pages

730-738

Published online

2022-09-16

Page views

4676

Article views/downloads

1227

DOI

10.5603/CJ.a2022.0087

Pubmed

36117294

Bibliographic record

Cardiol J 2022;29(5):730-738.

Keywords

cardiovascular prevention
hypertension
hypercholesterolemia
single-pill combination (SPC)

Authors

Krzysztof J. Filipiak
Miguel Camafort Babkowski
Matteo Cameli
Stefano Carugo
Claudio Ferri
Djamshid B. Irisov
Krzysztof Narkiewicz
Ulugbek Nizamov
Leopoldo Pérez de Isla
Anna Tomaszuk-Kazberuk
Andrea Ungar
Aleksandra Gąsecka

References (70)
  1. Parati G, Kjeldsen S, Coca A, et al. Adherence to single-pill versus free-equivalent combination therapy in hypertension: a systematic review and meta-analysis. Hypertension. 2021; 77(2): 692–705.
  2. Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009; 122(3): 290–300.
  3. Tazerji SS, Shahabinejad F, Tokasi M, et al. Global data analysis and risk factors associated with morbidity and mortality of COVID-19. Gene Rep. 2022; 26: 101505.
  4. Szarpak L, Filipiak KJ, Skwarek A, et al. Outcomes and mortality associated with atrial arrhythmias among patients hospitalized with COVID-19: A systematic review and meta-analysis. Cardiol J. 2022; 29(1): 33–43.
  5. Szarpak L, Rafique Z, Gasecka A, et al. A systematic review and meta-analysis of effect of vitamin D levels on the incidence of COVID-19. Cardiol J. 2021; 28(5): 647–654.
  6. Szarpak L, Pruc M, Gasecka A, et al. Should we supplement zinc in COVID-19 patients? Evidence from a meta-analysis. Pol Arch Intern Med. 2021; 131(9): 802–807.
  7. Szarpak L, Mierzejewska M, Jurek J, et al. Effect of coronary artery disease on covid-19-prognosis and risk assessment: a systematic review and meta-analysis. Biology (Basel). 2022; 11(2).
  8. Kaminska H, Szarpak L, Kosior D, et al. Impact of diabetes mellitus on in-hospital mortality in adult patients with COVID-19: a systematic review and meta-analysis. Acta Diabetol. 2021; 58(8): 1101–1110.
  9. Di Ciaula A, Krawczyk M, Filipiak KJ, et al. Noncommunicable diseases, climate change and iniquities: what COVID-19 has taught us about syndemic. Eur J Clin Invest. 2021; 51(12): e13682.
  10. Gąsecka A, Borovac JA, Guerreiro RA, et al. Thrombotic complications in patients with COVID-19: pathophysiological mechanisms, diagnosis, and treatment. Cardiovasc Drugs Ther. 2021; 35(2): 215–229.
  11. Olszanecka-Glinianowicz M, Dudek D, Filipiak KJ, et al. Letter to Editor. Treatment of overweight and obesity during and after a pandemic. Let's not wait for the development of complications — new guidelines for doctors. Psychiatr Pol. 2020; 54(6): 1263–1268.
  12. Sisti N, Valente S, Mandoli GE, et al. COVID-19 in patients with heart failure: the new and the old epidemic. Postgrad Med J. 2021; 97(1145): 175–179.
  13. Gasecka A, Pruc M, Kukula K, et al. Post-COVID-19 heart syndrome. Cardiol J. 2021; 28(2): 353–354.
  14. Gąsecka A, Filipiak KJ, Jaguszewski MJ. Impaired microcirculation function in COVID-19 and implications for potential therapies. Cardiol J. 2020; 27(5): 485–488.
  15. Pruc M, Merza Y, Filipiak KJ, et al. Treatment prospects for post-COVID-19 cardiac patients. Cardiol J. 2022; 29(3): 533–534.
  16. Torlasco C, Faini A, Pengo MF, et al. May Measurement Month 2019: an analysis of blood pressure screening results from italy. Eur Heart J Suppl. 2021; 23(Suppl B): B77–B81.
  17. Cicero AFG, Grassi D, Tocci G, et al. Nutrients and nutraceuticals for the management of high normal blood pressure: an evidence-based consensus document. High Blood Press Cardiovasc Prev. 2019; 26(1): 9–25.
  18. Del Pinto R, Grassi G, Ferri C, et al. Diagnostic and therapeutic approach to sleep disorders, high blood pressure and cardiovascular diseases: a consensus document by the italian society of hypertension (SIIA). High Blood Press Cardiovasc Prev. 2021; 28(2): 85–102.
  19. De Feo M, Del Pinto R, Pagliacci S, et al. Real-world hypertension prevalence, awareness, treatment, and control in adult diabetic individuals: an italian nationwide epidemiological survey. High Blood Press Cardiovasc Prev. 2021; 28(3): 301–307.
  20. Del Pinto R, Pagliacci S, De Feo M, et al. Prevalence of hypertension and associated cardiovascular risk factors among pharmacies customers: an Italian nationwide epidemiological survey. Eur J Prev Cardiol. 2020; 27(11): 1228–1230.
  21. Del Pinto R, Grassi G, Muiesan M, et al. World Hypertension Day 2021 in Italy: Results of a Nationwide Survey. High Blood Press Cardiovasc Prev. 2022; 29(4): 353–359.
  22. Lázaro P, Pérez de Isla L, Watts GF, et al. Cost-effectiveness of a cascade screening program for the early detection of familial hypercholesterolemia. J Clin Lipidol. 2017; 11(1): 260–271.
  23. Burnier M, Polychronopoulou E, Wuerzner G. Hypertension and drug adherence in the elderly. Front Cardiovasc Med Frontiers. 2020; 7: 49.
  24. Torlasco C, Faini A, Makil E, et al. Nation-wide hypertension screening in Italy: data from May Measurements Month 2017-Europe. Eur Heart J Suppl. 2019; 21(Suppl D): D66–D70.
  25. Hayes TL, Larimer N, Adami A, et al. Medication adherence in healthy elders: small cognitive changes make a big difference. J Aging Health. 2009; 21(4): 567–580.
  26. Rita DP, Dobre M, Pagliacci S, et al. Impact of guidelines on hypertension control in the elderly. Curr Pharm Des. 2021; 27(16): 1952–1959.
  27. Torlasco C, Faini A, Ferri C, et al. May Measurement Month 2018: an analysis of blood pressure screening results from Italy. Eur Heart J Suppl. 2020; 22(Suppl H): H70–H73.
  28. Lapi F, Lucenteforte E, Moschini M, et al. Representativeness of the "Fiesole Misurata" study database for use in pharmaco-epidemiological investigations on adherence to antihypertensive medications. Aging Clin Exp Res. 2013; 25(4): 433–445.
  29. Burnier M, Egan BM. Adherence in hypertension: a review of prevalence, risk factors, impact, and management. Circ Res. 2019; 124(7): 1124–1140.
  30. Abegaz TM, Shehab A, Gebreyohannes EA, et al. Nonadherence to antihypertensive drugs: A systematic review and meta-analysis. Medicine (Baltimore). 2017; 96(4): e5641.
  31. Malo S, Aguilar-Palacio I, Feja C, et al. Effect of patient and treatment factors on persistence with antihypertensive treatment: a population-based study. PLoS One. 2021; 16(1): e0245610.
  32. Del Pinto R, Desideri G, Ferri C, et al. Real-world antihypertensive treatment patterns, treatment adherence, and blood pressure control in the elderly: an Italian awareness-raising campaign on hypertension by senior Italia FederAnziani, the Italian Society of Hypertension and the Italian Federation of General Practitioners. High Blood Press Cardiovasc Prev. 2021; 28(5): 457–466.
  33. Saltijeral A, de Isla LP, Alonso R, et al. Attainment of LDL cholesterol treatment goals in children and adolescents with familial hypercholesterolemia. The SAFEHEART follow-up registry. Rev Esp Cardiol (Engl Ed). 2017; 70(6): 444–450.
  34. Corrao G, Nicotra F, Parodi A, et al. Cardiovascular protection by initial and subsequent combination of antihypertensive drugs in daily life practice. Hypertension. 2011; 58(4): 566–572.
  35. Genovesi S, Parati G, Giussani M, et al. How to apply European and American Guidelines on high blood pressure in children and adolescents. A position paper endorsed by the Italian Society of Hypertension and the Italian Society of Pediatrics. High Blood Press Cardiovasc Prev. 2020; 27(3): 183–193.
  36. Urtaran-Laresgoiti M, Nuño-Solinís R, Urizar E, et al. [The approach to hypercholesterolemia in health strategies and plans in Spain: present situation and future proposals]. An Sist Sanit Navar. 2021; 44(3): 339–350.
  37. Ferri C, Ferri L, Desideri G. Management of hypertension in the elderly and frail elderly. High Blood Press Cardiovasc Prev. 2017; 24(1): 1–11.
  38. Bruno RM, Taddei S, Borghi C, et al. Italian Society of Arterial Hypertension (SIIA) position paper on the role of renal denervation in the management of the difficult-to-treat hypertensive patient. High Blood Press Cardiovasc Prev. 2020; 27(2): 109–117.
  39. Alonso R, Muñiz-Grijalvo O, Díaz-Díaz JL, et al. Efficacy of PCSK9 inhibitors in the treatment of heterozygous familial hypercholesterolemia: A clinical practice experience. J Clin Lipidol. 2021; 15(4): 584–592.
  40. Del Pinto R, Ferri C. Hypertension management at older age: an update. High Blood Press Cardiovasc Prev. 2019; 26(1): 27–36.
  41. Tocci G, Presta V, Ferri C, et al. Blood pressure targets achievement according to 2018 ESC/ESH guidelines in three european excellence centers for hypertension. High Blood Press Cardiovasc Prev. 2020; 27(1): 51–59.
  42. Volpe M, Gallo G, Modena MG, et al. Updated recommendations on cardiovascular prevention in 2022: an executive document of the Italian Society of Cardiovascular Prevention. High Blood Press Cardiovasc Prev. 2022; 29(2): 91–102.
  43. Grassi G, Del Pinto R, Agabiti Rosei C, et al. Reduction of high cholesterol levels by a preferably fixed-combination strategy as the first step in the treatment of hypertensive patients with hypercholesterolemia and high/very high cardiovascular risk: a consensus document by the Italian Society of Hypertension. High Blood Press Cardiovasc Prev. 2022; 29(2): 105–113.
  44. Wożakowska-Kapłon B, Filipiak KJ, Mamcarz A, et al. [Actual problems of dyslipidaemia treatment in Poland - 2nd Declaration of Sopot. Experts' Group Consensus endorsed by the Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy]. Kardiol Pol. 2014; 72(9): 847–853.
  45. Pérez de Isla L, Arroyo-Olivares R, Muñiz-Grijalvo O, et al. Long-term effect of 2 intensive statin regimens on treatment and incidence of cardiovascular events in familial hypercholesterolemia: The SAFEHEART study. J Clin Lipidol. 2019; 13(6): 989–996.
  46. Weng TC, Yang YHK, Lin SJ, et al. A systematic review and meta-analysis on the therapeutic equivalence of statins. J Clin Pharm Ther. 2010; 35(2): 139–151.
  47. Mukhtar RYA, Reid J, Reckless JPD. Pitavastatin. Int J Clin Pract. 2005; 59(2): 239–252.
  48. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020; 41(1): 111–188.
  49. Pęczek P, Leśniewski M, Mazurek T, et al. Antiplatelet effects of PCSK9 inhibitors in primary hypercholesterolemia. Life (Basel). 2021; 11(6).
  50. Rogula S, Błażejowska E, Gąsecka A, et al. Inclisiran-silencing the cholesterol, speaking up the prognosis. J Clin Med. 2021; 10(11).
  51. Averna M, Banach M, Bruckert E, et al. Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force. Atherosclerosis. 2021; 325: 99–109.
  52. Escobar C, Anguita M, Arrarte V, et al. Recommendations to improve lipid control. Consensus document of the Spanish Society of Cardiology. Rev Esp Cardiol (Engl Ed). 2020; 73(2): 161–167.
  53. Gąsecka A, Rogula S, Szarpak Ł, et al. LDL-cholesterol and platelets: insights into their interactions in atherosclerosis. Life (Basel). 2021; 11(1).
  54. Lafeber M, Spiering W, van der Graaf Y, et al. The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) and the risk of vascular morbidity and mortality in patients with coronary artery disease. Am Heart J. 2013; 166(2): 282–289.e1.
  55. Tykarski A, Filipiak K, Januszewicz A, et al. 2019 Guidelines for the management of hypertension — part 1–7. Arterial Hypertension. 2019; 23(2): 41–87.
  56. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018; 39: 3021–3104.
  57. Rea F, Corrao G, Merlino L, et al. Early cardiovascular protection by initial two-drug fixed-dose combination treatment vs. monotherapy in hypertension. Eur Heart J. 2018; 39(40): 3654–3661.
  58. Egan BM, Bandyopadhyay D, Shaftman SR, et al. Initial monotherapy and combination therapy and hypertension control the first year. Hypertension. 2012; 59(6): 1124–1131.
  59. Tykarski A, Widecka K, Narkiewicz K, et al. Single-pill combinations (SPCs) and treatment of arterial hypertension in Poland. Expert consensus statement of the Polish Society of Hypertension and Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy. Kardiol Pol. 2017; 75(12): 1357–1367.
  60. Czech M, Boguslawski S, Smaga A, et al. Use of single pill combinations in the treatment of arterial hypertension in Poland: The current practice and guidelines, the impact on reimbursement spending and patient co-payment. Cardiol J. 2022; 29(3): 405–412.
  61. Dezii CM, Dezii CM. A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension. Manag Care. 2001; 10(2 Suppl): 6–10.
  62. Campana E, Cunha V, Glaveckaite S, et al. The use of single-pill combinations as first-line treatment for hypertension: translating guidelines into clinical practice. J Hypertens. 2020; 38(12): 2369–2377.
  63. Lopatowska P, Mlodawska E, Tomaszuk-Kazberuk A, et al. Adhering to the principles of clinical pharmacology - the correct fixed combinations of antihypertensive drugs. Expert Rev Clin Pharmacol. 2018; 11(2): 165–170.
  64. Filipiak KJ, Tomaniak M, Płatek AE, et al. Negative predictors of treatment success in outpatient therapy of arterial hypertension in Poland. Results of the CONTROL NT observational registry. Kardiol Pol. 2018; 76(2): 353–361.
  65. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000; 342(3): 145–153.
  66. Siewaszewicz E, Filipiak KJ, Opolski G, et al. Aldosterone antagonists in post-myocardial infarction heart failure-clinical practice in Poland-reasons, methods and preliminary results of a questionnaire-based survey. Pol Prz Kardiol. 2010; 12: 9–17.
  67. Mamcarz A, Filipiak KJJ, Drożdż J, et al. [Loop diuretics: old and new ones — which one to choose in clinical practice? Experts' Group Consensus endorsed by the Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy and Working Group on Heart Failure]. Kardiol Pol. 2015; 73(3): 225–232.
  68. Surma S, Romańczyk M, Filipiak KJ. Ranolazine — could an antianginal drug be used in stroke prevention? Int J Cardiol Cardiovasc Risk Prev. 2022; 14: 200137.
  69. Filipiak K, Gąsecka A, Lewandowski M, et al. Attitudes of Polish physicians towards new antihypertensive agents — a final report from the ALMONDS survey. Folia Cardiol. 2016; 11(2): 85–95.
  70. Nucera G, Chirico F, Rafique Z, et al. Need to update cardiological guidelines to prevent COVID-19 related myocardial infarction and ischemic stroke. Cardiol J. 2022; 29(1): 174–175.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl